Latest Hotspot

EMA Approves Review of Tisotumab Vedotin for Advanced Cervical Cancer Therapy

11 February 2024
3 min read

Genmab A/S in collaboration with Pfizer, Inc. has shared the news that the European Medicines Agency has commenced evaluation of the submitted documents for the marketing authorization of tisotumab vedotin. This medicinal product is an antibody-drug conjugate, specifically created to address the needs of adults who are suffering from cervical cancer that has either returned or spread, and who have experienced disease advancement despite undergoing systemic treatment. Upon receiving the green light, tisotumab vedotin is poised to become the inaugural ADC to acquire marketing approval within the European Union for the treatment of individuals affected by cervical cancer.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The MAA submission is anchored in outcomes from the international, multicenter, Phase 3 innovaTV 301 trial. This pivotal study showcased the enhanced efficacy of tisotumab vedotin in extending overall survival, delaying disease progression, and achieving a verified response in treating individuals with recurrent or metastatic cervical cancer after prior therapy, outperforming standard chemotherapy regimens.

Included in the MAA dossier were findings from the innovaTV 204 trial—a key Phase 2 research focusing on the use of TIVDAK as a single-agent treatment for similar patient groups. Tisotumab vedotin's safety parameters reported in innovaTV 301 align with the profile documented within the prescribing guidelines in the United States.

"With the MAA assessment process underway, we've reached a crucial step in our mission to offer a novel treatment for those battling with recurring or advanced stages of cervical cancer," remarked Jan van de Winkel, Ph.D., Genmab's CEO. "Given the urgent requirement for new treatments for these individuals, we are unwavering in our pursuit to present better options for women suffering from this aggressive illness."

Highlighting the advancement, Roger Dansey, M.D., Pfizer's Chief Development Officer for Oncology, noted, "This milestone underscores our efforts in widening access to tisotumab vedotin for patients enduring recurrent or metastatic cervical cancer. As we push forward, we are committed to working in tandem with health regulators, striving to introduce an innovative treatment option for those contending with this challenging condition."

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of February 8, 2024, there are 2 investigational drugs for the Tubulin and tissue factor target, including 28 indications, 8 R&D institutions involved, with related clinical trials reaching 21, and as many as 331 patents.

tisotumab vedotin-tftv is an approved ADC and monoclonal antibody that targets tubulin and tissue factor. It has shown promise in the treatment of various cancers and has received regulatory approvals, including priority review and accelerated approval. The drug has reached the highest phase of development globally and is currently in phase 3 in China. Its first approval was granted in the United States, and it is indicated for multiple cancer types, including uterine cervical cancer, colorectal cancer, and non-small cell lung cancer.

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

A Complete Guide to Searching Magnesium citrate on Synapse
Drug Insights
2 min read
A Complete Guide to Searching Magnesium citrate on Synapse
11 February 2024
Magnesium citrate is a type of small molecule drug that is a combination of magnesium and citric acid in a 1:1 ratio.
Read →
Ascendis Pharma Launches YORVIPATH® for Adult Hypoparathyroidism in Germany and Austria
Latest Hotspot
3 min read
Ascendis Pharma Launches YORVIPATH® for Adult Hypoparathyroidism in Germany and Austria
11 February 2024
Ascendis Pharma unveils its second TransCon™ offering: YORVIPATH® hits markets in Germany and Austria, targeting chronic hypoparathyroidism in adults.
Read →
Using Synapse for Your Cefdinir Research: An Easy Guide
Drug Insights
2 min read
Using Synapse for Your Cefdinir Research: An Easy Guide
11 February 2024
Cefdinir, marketed under the brand name Omnicef, is a small molecule drug that acts as a penicillin-binding protein (PBP) inhibitor and a cell wall inhibitor.
Read →
FDA Approves NeuroBo Pharmaceuticals' Phase 1 Study of Obesity Drug DA-1726
Latest Hotspot
3 min read
FDA Approves NeuroBo Pharmaceuticals' Phase 1 Study of Obesity Drug DA-1726
11 February 2024
NeuroBo Pharmaceuticals has received approval from the FDA for a Phase 1 clinical study of DA-1726, a new drug aimed at managing obesity.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.